MAOB and Parkinson disease: Selegiline, a selective MAO‐B inhibitor, has been found to improve life expectancy in patients suffering from PD when combined with L‐DOPA; it is now widely used as a treatment option for the disease (Filip & Kolibas, 1999; Guay, 2006).